CANCER VACCINES FOR
MELANOMA
Melanoma is where cancer vaccines have the most clinical traction right now. One regulatory approval in 2024. A major Phase III trial running. More active programs than any other solid tumor. If you have an advanced melanoma diagnosis, the vaccine evidence here is the most actionable in the entire field.
analyticsAt a Glance
- check_circlemRNA-4157 (Moderna/MSD) reduced melanoma recurrence by 44% in combination with pembrolizumab
- check_circlePersonalised neoantigen vaccines are generated from each patient's tumour sequencing results
- check_circlePhase III trials in high-risk resected melanoma are now underway globally
- check_circleVaccine therapy is used alongside checkpoint inhibitors, not as a standalone treatment
What This Means for Patients
Advanced melanoma used to be one of the grimmer diagnoses in oncology. Checkpoint inhibitors changed outcomes significantly โ but that still leaves patients who didn't respond, or whose responses didn't last. Cancer vaccines are now targeting exactly that population. Melanoma is inherently immunogenic โ it generates more immune activity than most tumors โ which makes it a particularly receptive setting for vaccine approaches. That's why this is where the field has moved fastest.
Key Developments in Melanoma Vaccine Therapy
Three landmark programs and why each matters โ not just for melanoma but for the entire therapeutic vaccine field.
Lifileucel (Amtagvi) โ FDA Approved February 2024
TIL therapy โ tumor-infiltrating lymphocytes expanded from the patient's own tumor tissue and returned in large numbers. Approved for unresectable or metastatic melanoma after prior PD-1 therapy. The first regulatory approval for any non-engineered cell-based therapeutic cancer treatment anywhere in the world. Its significance extends well beyond melanoma.
mRNA-4157/V940 โ Phase III Underway
Moderna/Merck personalized mRNA neoantigen vaccine. Phase II (KEYNOTE-942) showed ~44% lower recurrence or death versus pembrolizumab alone in high-risk resected melanoma. Results held at extended follow-up. Advanced directly to Phase III. If results confirm, implications extend across the entire personalized vaccine field.
Adjuvant Programs for High-Risk Resected Melanoma
Multiple trials enrolling for adjuvant vaccine therapy โ given after surgery to reduce recurrence risk rather than treat existing metastatic disease. Stage IIB/C and Stage III melanoma patients are the target population. Ask about these during post-surgery evaluation, not after recurrence.
Key Numbers
- Feb 2024Lifileucel FDA Approval DateFirst-ever regulatory approval for a non-engineered, cell-based therapeutic cancer treatment. A landmark for the entire field โ not just for melanoma patients.
- ~44%Recurrence/Death Reduction (Phase II)mRNA-4157/V940 plus pembrolizumab vs pembrolizumab alone in high-risk melanoma. The result that pushed this program directly into Phase III trials.
- High TMBMelanoma's Biological AdvantageHigh tumor mutational burden โ common in melanoma โ creates more neoantigens for vaccine targeting. It's why response rates tend to be higher here than in other solid tumors.
Who This Is Relevant For
Metastatic or unresectable melanoma after PD-1 therapy progression: lifileucel is a commercially available option โ discuss it at your next appointment. High-risk resected melanoma (Stage IIB/C, III): adjuvant vaccine trials are actively enrolling. BRAF-mutated melanoma after both targeted therapy and immunotherapy: vaccine-based next steps are being increasingly evaluated.
Benefits and Limitations
Benefits
- Most mature vaccine evidence in any solid tumorResponse rates tend to be higher than in other cancers. Durability data is more mature. Some complete TIL therapy responses have held for years.
- Approved options exist โ not just trialsLifileucel is a commercially approved product for eligible patients with metastatic disease after PD-1 progression.
- Biology works in melanoma's favorHigh mutational burden, relatively permissive immune environment โ more immune targets and more immune activity than most solid tumors.
Limitations
- TIL therapy is logistically demandingRequires surgery for tumor harvest, weeks of cell expansion, lymphodepleting chemotherapy, and hospital admission. Not every patient is physically well enough for this process.
- Not every manufacturing run succeedsTIL expansion and lifileucel production have documented manufacturing failure rates. Ask specifically what the plan is if manufacturing doesn't produce a viable product.
- Uveal melanoma is a separate diseaseLower mutational burden, distinct molecular profile, substantially less response to cutaneous melanoma immunotherapy approaches. Ask specifically about uveal-focused programs.
When to Consider This Option
After progression on PD-1 therapy: the conversation about lifileucel belongs at the next appointment after progression is confirmed. For high-risk resected disease: ask about adjuvant trial programs during your post-surgery evaluation โ not after recurrence has happened.
Frequently Asked Questions
Melanoma Vaccine Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Melanoma After PD-1 Therapy? Vaccine Options Exist.
Whether lifileucel, a neoantigen vaccine trial, or an adjuvant program applies to your specific case depends on your treatment history, disease status, and access. Upload your reports and our specialist team will assess the options now available.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.